Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy.
Intrahepatic cholangiocarcinoma
Macroscopic type
Proton beam therapy
Survival
Unresectable ICC
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
27 Dec 2019
27 Dec 2019
Historique:
received:
18
09
2019
accepted:
19
12
2019
entrez:
29
12
2019
pubmed:
29
12
2019
medline:
1
7
2020
Statut:
epublish
Résumé
The effectiveness of proton beam therapy (PBT) as initial treatment for patients with unresectable intrahepatic cholangiocarcinoma (ICC) is unclear, particularly as related to ICC histological subtypes. We performed this study to address this gap in knowledge. Thirty-seven patients with unresectable ICC who underwent PBT as their initial treatment were evaluated. Twenty-seven patients had Child-Pugh class A liver function, 11 exhibited jaundice, and 10 had multiple tumors. Nineteen, 7, and 11 tumors were classified as mass forming (MF), periductal infiltrating (PI), and intraductal growth (IG) types, respectively, based on gross appearance in imaging studies. Patients were classified into the curative group (n = 25) and palliative group (n = 12) depending on whether the planning target volume covered all the macroscopic tumors. The 1- and 2-year overall survival rates were 60.3, and 41.4%, respectively; the median survival time (MST) was 15 months for all patients. The MSTs for curative and palliative groups were 25 and 7 months, respectively. Curative treatment and adjuvant chemotherapy significantly improved overall survival, while the presence of periductal infiltrating type tumors was a negative prognostic factor. In the curative group, the 1- and 2-year local control rates were 100 and 71.5%, respectively, while the 1-, and 2-year progression-free survival rates were 58.5, and 37.6%, respectively. No severe acute toxicities were observed. Three patients experienced grade 3 biliary tract infection, although it was unclear whether this was radiotherapy-related. PBT may yield to improve survival and local tumor control among patients with unresectable ICC.
Sections du résumé
BACKGROUND
BACKGROUND
The effectiveness of proton beam therapy (PBT) as initial treatment for patients with unresectable intrahepatic cholangiocarcinoma (ICC) is unclear, particularly as related to ICC histological subtypes. We performed this study to address this gap in knowledge.
METHODS
METHODS
Thirty-seven patients with unresectable ICC who underwent PBT as their initial treatment were evaluated. Twenty-seven patients had Child-Pugh class A liver function, 11 exhibited jaundice, and 10 had multiple tumors. Nineteen, 7, and 11 tumors were classified as mass forming (MF), periductal infiltrating (PI), and intraductal growth (IG) types, respectively, based on gross appearance in imaging studies. Patients were classified into the curative group (n = 25) and palliative group (n = 12) depending on whether the planning target volume covered all the macroscopic tumors.
RESULTS
RESULTS
The 1- and 2-year overall survival rates were 60.3, and 41.4%, respectively; the median survival time (MST) was 15 months for all patients. The MSTs for curative and palliative groups were 25 and 7 months, respectively. Curative treatment and adjuvant chemotherapy significantly improved overall survival, while the presence of periductal infiltrating type tumors was a negative prognostic factor. In the curative group, the 1- and 2-year local control rates were 100 and 71.5%, respectively, while the 1-, and 2-year progression-free survival rates were 58.5, and 37.6%, respectively. No severe acute toxicities were observed. Three patients experienced grade 3 biliary tract infection, although it was unclear whether this was radiotherapy-related.
CONCLUSION
CONCLUSIONS
PBT may yield to improve survival and local tumor control among patients with unresectable ICC.
Identifiants
pubmed: 31881895
doi: 10.1186/s13014-019-1451-5
pii: 10.1186/s13014-019-1451-5
pmc: PMC6935160
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241Références
Int J Radiat Oncol Biol Phys. 2013 Sep 1;87(1):22-32
pubmed: 23219567
Cancer Chemother Pharmacol. 2010 May;65(6):1101-7
pubmed: 19707761
Cancer. 2007 Sep 15;110(6):1307-12
pubmed: 17628484
J Gastroenterol Hepatol. 2008 May;23(5):766-70
pubmed: 17868336
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):831-6
pubmed: 19304408
Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):407-21
pubmed: 12023146
Jpn J Clin Oncol. 1999 Mar;29(3):147-50
pubmed: 10225697
Cancer. 2001 Nov 1;92(9):2374-83
pubmed: 11745293
J Radiat Res. 2017 May 1;58(3):357-362
pubmed: 27974509
J Clin Oncol. 2008 Feb 1;26(4):657-64
pubmed: 18172187
Radiat Oncol. 2014 Jan 14;9:26
pubmed: 24422711
J Clin Oncol. 2016 Jan 20;34(3):219-26
pubmed: 26503201
Radiother Oncol. 2015 Nov;117(2):322-7
pubmed: 26385268
Ann Surg. 1990 Mar;211(3):277-87
pubmed: 2155591
J Hepatobiliary Pancreat Surg. 2002;9(2):233-6
pubmed: 12140612
J Gastroenterol Hepatol. 2015 May;30(5):957-63
pubmed: 25376272
J Clin Oncol. 2016 Feb 10;34(5):460-8
pubmed: 26668346
J Gastroenterol Hepatol. 2019 Jun;34(6):1108-1115
pubmed: 30242888
Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):992-5
pubmed: 21543162
Cancer. 2005 Aug 15;104(4):794-801
pubmed: 15981284
Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):951-8
pubmed: 15465214
Surgery. 2001 Apr;129(4):401-7
pubmed: 11283529
Int J Radiat Oncol Biol Phys. 1997 Nov 1;39(4):929-35
pubmed: 9369143
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e529-35
pubmed: 22284041
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):460-6
pubmed: 19427743
Int J Clin Oncol. 2004 Dec;9 Suppl 3:1-82
pubmed: 15818867
Br J Cancer. 2008 Sep 16;99(6):862-7
pubmed: 19238628
World J Surg. 2002 Jun;26(6):687-93
pubmed: 12053220
World J Surg. 2009 Jun;33(6):1247-54
pubmed: 19294467
World J Gastroenterol. 2008 Nov 14;14(42):6458-66
pubmed: 19030196
Gut Liver. 2009 Dec;3(4):298-305
pubmed: 20431764
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404